<DOC>
	<DOCNO>NCT02269969</DOCNO>
	<brief_summary>Effective antimicrobial use burn population important since population increase risk infection stay hospital result burn injury . Tobramycin antibiotic activity common burn wound associate pathogen , Pseudomonas Aeruginosa , use become increasingly relevant due increase incidence bacterial resistance currently utilized antibiotic . Once daily dose tobramycin safely effectively use majority infect patient many year propose benefit optimize antibacterial activity reduce nephrotoxicity compare traditional dosing . But , daily dose regimen yet validate burn population . The purpose study validate plausibility daily tobramycin dose burn population intent determine safe , effective , efficient dose regimen population .</brief_summary>
	<brief_title>Once Daily Aminoglycoside Pharmacokinetics Optimal Dosing Burn Population : A Prospective Study</brief_title>
	<detailed_description />
	<mesh_term>Burns</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Adult burn patient ( â‰¥ 18 year old ) Total burn surface area le 20 % At least 48 hour time initial burn injury event Has suspect confirm infection Has receiving antibiotic therapy least 24 hour Pediatric patient ( &lt; 18 year old ) ; Pregnant Documented history cochlear vestibular injury Creatinine clearance &lt; 50 ml/min Requiring modality dialysis Has receiving antibiotic therapy longer 72 hour Known allergy adverse reaction aminoglycoside antibiotic Known allergy adverse reaction sulfites Diagnosis Parkinson 's disease myasthenia gravis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Aminoglycoside</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Once daily dose</keyword>
</DOC>